CAS: 198904-53-9; 4-(Thiazol-2-yl)Benzaldehyde

上下游产品

CAS号3034-53-5 2-溴噻唑 | CAS号87199-17-5 4-甲酰基苯硼酸 | CAS号24856-58-4 4-溴苯甲醛二甲基缩醛 | CAS号454678-91-2 [4-(1,3-噻唑-2-基)苯基]甲醇

📜2-溴噻唑,4-溴苯甲醛二甲缩醛置于盐酸体系中,用 四氢呋喃,正己烷,水 用作溶剂,化学反应生成4-(1,3-噻唑-2-基)苯甲醛
参考文献:Antivirally Active Heterocyclic Azahexane Derivatives
标题:Antivirally Active Heterocyclic Azahexane Derivatives
摘要:以下是公式i*的描述,##str1## 其中r.Sub.1是低级烷氧羰基,R.Sub.2是二级或三级低级烷基或低级烷基硫基-低级烷基,R.Sub.3是未取代或由一个或多个低级烷氧基团取代的苯基,或者是c.Sub.4-C.Sub.8环烷基,R.Sub.4是苯基或环己基,每个在4位上取代有不饱和杂环,该杂环通过环碳原子连接,具有5到8个环原子,含有1到4个选自氮,氧,硫,亚磺酰基(--So--)和磺酰基(--So.Sub.2--)的杂原子,并且未取代或由低级烷基或苯基-低级烷基取代,R.Sub.5独立于r.Sub.2,具有r.Sub.2所述的一个含义,而r.Sub.6独立于r.Sub.1,是低级烷氧羰基,或其盐类,前提是至少存在一个成盐基团.这些化合物是逆转录病毒天冬氨酸蛋白酶的抑制剂,例如,可以用于治疗艾滋病.它们展现出卓越的药效动力学特性.

专利信息

专利号:US-9795613-B2
优先权日:2014-12-10
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL; GLYNN DANIEL; MILLS MARK
权利人:CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.

专利号:US-9187522-B2
优先权日:2011-12-12
标题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC
摘要:The invention relates to compounds that modulate the glucagon-like peptide 1 (GLP-1) receptor, methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds are act as modulators or potentiators of GLP-1 receptor on their own, or with receptor ligands including GLP-1 peptides GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.

专利号:US-9598430-B2
优先权日:2013-06-11
标 题 :GLP-1 receptor modulators
发明人：BOEHM MARCUS F; MARTINBOROUGH ESTHER; MOORJANI MANISHA; TAMIYA JUNKO; HUANG LIMING; YEAGER ADAM R; BRAHMACHARY ENUGURTHI; FOWLER THOMAS; NOVAK ANDREW; MEGHANI PREMJI; KNAGGS MICHAEL
权利人:RECEPTOS INC; CELGENE INT II SÀRL
摘要:Compounds are provided that modulate the glucagon-like peptide 1 (GLP-1) receptor, as well as methods of their synthesis, and methods of their therapeutic and/or prophylactic use. Such compounds can act as modulators or potentiators of GLP-1 receptor on their own, or with incretin peptides such as GLP-1(7-36) and GLP-1(9-36), or with peptide-based therapies, such as exenatide and liraglutide, and have the following general structure (where “ â€? represents either or both the R and S form of the compound): n nwhere A, B, C, Y 1 , Y 2 , Z, R 1 , R 2 , R 3 , R 4 , R 5 , W 1 , n, p and q are as defined herein.